Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 285
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.]...
MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes...
The Pitfalls and Challenges of Psychedelic Medicine
Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and...
Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT
Red Light Holland’s Psychedelic Virtual Reality Experience, Wisdom, Narrated by Global...
PharmaDrug Announces Drug-Repurposing Expert Moshe Rogosnitzky Joins Sairiyo Therapeutics Scientific and...
Numinus to expand state-of-the-art psychedelics research laboratory
Load more